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Background: Long-term longitudinal studies of lung function from childhood to adulthood are
important in linking our understanding of childhood risk factors to adult disease. Airway hyper-
responsiveness has been shown to independently affect lung function growth in studies of
adolescence. The objective of the study was to test the hypothesis that airway hyperrespon-
siveness has an independent deleterious effect on lung function in adolescence that extends
into adulthood.
Methods: A random population sample (n Z 983) aged 7e17 from Copenhagen was followed
longitudinally for 20 years with four examinations.
Results: A total of 780 (79.3%) subjects contributed with lung function measurements
and bronchial provocation testing. Among these, 170 (21.8%) had airway hyperresponsiveness
at one examination or more during the study period. There was no difference in initial FEV1
levels between subjects with and without airway hyperresponsiveness. In a repeated measures
regression model with adjustment for asthma and smoking, airway hyperresponsiveness was
independently associated with reduced rates of growth in lung function in both sexes of
23 ml/year. Reduced growth rates resulted in deficits in maximal attained level of lung func-
tion at age 18, which persisted throughout the follow-up until the last examination at age 27
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Airway hyperresponsiveness and lung function 753Conclusion: Airway hyperresponsiveness has an independent deleterious effect on lung func-
tion development from 7 to 37 years resulting in a lower maximal attained lung function
and persistent deficits in lung function in adulthood.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Development of lung function during childhood and
adolescence determines the maximal attained lung func-
tion in young adulthood, and this level together with the
rate of decline in lung function determines the subsequent
lung function levels during adult life [1,2]. As such, deficits
in maximal attained lung function may potentially
contribute to the risk of later development of chronic
obstructive pulmonary disease (COPD). Factors that influ-
ence lung function growth in children and adolescents are
therefore interesting to study, as well as factors with ef-
fects on lung function that extend beyond the growth
phase.
Only one general population study has studied lung
function development from birth to the age of 22 [3]. In this
study, the authors found, that children with low lung
function in infancy had significantly lower lung function at
the age of 22. Furthermore, they investigated the influence
of wheeze, smoking, atopy, and parental asthma on this
association, and found no modifying effects of these pa-
rameters on the development of lung function measures.
Two general population studies have addressed the in-
dependent effect of AHR on lung function in adolescents,
and found that AHR is related to short-term deficits in lung
function growth independently of asthmatic symptoms
[4,5]. One study found AHR to be the single most important
risk factor for reduced maximal level of lung function [6]. In
adult populations, AHR has been related to lung function
decline in individuals both with and without asthma [7]. We
therefore hypothesized that AHR may be independently
associated with lung function growth during adolescence in
the general population, and that this association possibly
have long-term effects extending into adulthood.
Consequently, the aim of this study was to investigate
the association between AHR and lung function develop-
ment from childhood to adulthood. Analyses were per-
formed on a non-selected cohort of subjects followed over
20 years from childhood to adulthood covering the ages
from 7 to 37 years.
Methods
Study subjects
Subjects participated in a prospective epidemiologic study
initiated in 1986 [8]. A random sample of subjects were
drawn from the civil registration list according to the year
of birth between 1969 and 1979, and the date of birth
during the first 7 days of each month of the year. As such,
983 children and adolescents aged 7e17 years from
Copenhagen were included. Follow-ups took place in 1992,
1998, and 2006 as a 20-year follow-up.Methods
Measurements of lung function
Measurements of forced expiratory volume in 1 s (FEV1) and
forced vital capacity (FVC) were performed on a 7-L dry
wedge spirometer (Vitalograph, Buckingham, UK) at all
examinations. Each measurement consisted of at least
three forced expiratory manoeuvres from total lung ca-
pacity to residual volume with a variation of less than 5%.
Manoeuvers were performed with the subjects in standing
position without use of nose-clip. The highest FEV1 and FVC
values were the reported in absolute values. For the first
and second examination, when subjects were still children
and adolescents, the reference values by Zapletal were
used to calculate FEV1%pred and FVC in percent of pre-
dicted value (FVC%pred) [9]. For the examinations three
and four, when subjects had become adults, the reference
values for pulmonary function testing published by the
European Community for Coal and Steel (ECCS) [10], was
used to calculate FEV1%pred and FVC%pred.
Before testing, subjects were instructed not to use
theophylline for at least 24 h, and short-acting beta-agonist
(SABA) for 6 h. When long-acting beta-agonists (LABA) and
leukotriene antagonists became available in Denmark,
subjects were asked not to use LABA for 12 h, and leuko-
triene antagonists for 24 h. They were allowed to continue
use of ICS. Subjects had no respiratory infections within 6
weeks of testing. Otherwise the examination was
postponed.
Bronchial challenge tests
Bronchial challenge tests were performed with histamine
according to the method described by Cockcroft et al. [11]
at the first three examinations, and with methacholine
according to the method of Yan et al. [12] at the fourth
examination. Cut-off was a fall in FEV1 of 20% or more at a
concentration of less than 8 mg/ml at the first examination,
due to constraints placed by the ethical committee at the
time, 16 mg/ml at the second and third examination, and a
dose less than 8 mmol at the fourth examination.
Height and weight
Height (in standing position without shoes) and weight were
measured, and body mass index (BMI) was calculated.
Case history
Case history was obtained in part by questionnaires and in
part by semi-structured interviews performed by a trained
physician at all examinations. Case history included data on
asthma, allergic diseases, and lifestyle factors.
Questions about asthma were adopted from studies by
the ATS, Division of Lung Disease of the National Heart,
Lung and Blood Institute [13] and Global Initiative for
Asthma (GINA) [14].
754 L. Harmsen et al.Smoking history was recorded and subjects were classi-
fied as current smokers, former smokers or never smokers.
In the analyses, former and current smokers were grouped
as ever smokers.
Statistical methods
Data were analysed with the statistical software package
SAS (SAS Institute Inc., Cary, NC). Repeated measures
regression analysis was used to study the pattern of lung
function development. Our model fitted two lines with
different slopes joining in a breakpoint at 18 years of age to
describe the growth phase followed by a plateau or decline
phase. The correlation between the unequally spaced
measurements was modelled by a power function of the
time between the measurements using Proc Mixed.
Dependent variable was FEV1 and the explanatory variables
were AHR, age, sex, asthma, and smoking. An interaction
term between sex and age was added to allow sex differ-
ences in lung function growth. The variable AHR was tested
in two versions: one that described a positive AHR test on at
least one occasion during the study (ever AHR), and one
that described AHR at the first examination of the subject.
The term “estimated values of FEV1” refers to the fitted
values calculated from the model.
The possible confounding of FEV1 by height was
addressed by fitting a model with height as dependent
variable and the same covariates as the model for FEV1.
This showed that the pattern of height growth was not
influenced by AHR or any other covariates besides age and
sex (p > 0.2). Therefore, height is not likely to have
confounded the relationship between FEV1 and the
covariates.
Differences in means were tested using parametric (t-
test) and non-parametric (ManneWhitney) tests where
appropriate. Differences in frequencies were tested using
Chi-square tests.
P-values below 0.05 were considered significant. All
subjects gave informed consent at each examination and
the study was approved by the ethics committee of
Copenhagen and Frederiksberg ((KF) 01 318737).Table 1 Characteristics of subjects included in the longitudina
1st examinationa (1986) 2nd examinationa (199
Males Females Males Female
N Z 228 N Z 242 N Z 321 N Z 34
Age (years) 12.2 (2.8) 12.4 (2.9) 18.5 (2.8) 18.7 (2.
BMI (kg/m2)y 18.6 (2.7) 19.1 (3.0) 21.6 (3.3) 21.4 (4.
FEV1 (L)
z 2.61 (1.0) 2.45 (0.7) 4.47 (0.85) 3.46 (0.
FVC (L)x 2.95 (1.1) 2.70 (0.8) 5.26 (1.00) 3.97 (0.
FEV1/FVC
k 0.88 (0.06) 0.91 (0.04) 0.85 (0.07) 0.87 (0.
AHRxx 22 (5.9) 12 (2.9) 54 (14.5) 49 (12
Values are given as mean (SD).
yp < 0.05 in 1998 and 2006; zp < 0.001 in 1992, 1998, and 2006; xpZ
1986, 1992, and 1998 and p Z 0.002 in 2006; xxp Z 0.02 in 2006.
Definition of abbreviations: AHR Z airway hyperresponsiveness, BM
FVC Z forced vital capacity.
a Differences between sexes were tested with t-tests for continuo
ferences were non-significant, unless otherwise stated.Results
For the longitudinal analysis of lung function development,
780 subjects (79.3%) were eligible and included. Of these,
148 subjects (19.0%) participated in all examinations, and
thus contributed with four lung function measurements.
244 subjects (31.3%), 246 subjects (31.5%), and 142 subjects
(18.2%) contributed with 3, 2, and 1 lung function mea-
surement, respectively.
The 203 subjects that were excluded in the study have
never been examined, thus we have no further information
on them besides sex and age. There was no significant
difference in the proportion of males (56%) and females
(44%) (p Z 0.07) among the excluded subjects, although
there was a tendency of more males than females not
participating. With regard to age, there was no significant
difference in the age-distribution between included and
excluded subjects (p Z 0.57).
Among the included subjects, there were equal pro-
portions of males (47.8%) and females (52.2%) (p Z 0.22).
Table 1 presents the characteristics of the subjects; the
proportion of subjects with airway obstruction (defined as
FEV1/FVC < 0.70) was 0.4%, 0.8%, 2.3%, and 2.7%, respec-
tively, at the four examinations. Table 2 presents the
prevalence of AHR, asthma and smoking. There was no
significant difference in prevalence of asthma between
sexes (p Z 0.06), although there was a slight tendency
towards more females having asthma than males. Further-
more, females smoked more frequently than males
(p < 0.001).
Among the 780 subjects, 170 (21.8%) had a positive AHR
test on at least one occasion during the study (ever AHR).
There was no difference in this prevalence between sexes
(p Z 0.9). Among the 170 subjects, 75 (44.1%) were AHR
positive at the first examination of the subject, and
significantly more males than females. Among the 95 sub-
jects that had ever AHR during the study but no positive
test at their first examination, 34 (35.8%) had positive AHR
tests at all their examinations after the first examination,
and 61 (64.2%) had positive AHR tests at some of theirl analyses.
2) 3rd examinationa (1998) 4th examinationa (2006)
s Males Females Males Females
1 N Z 233 N Z 299 N Z 130 N Z 166
9) 24.0 (2.9) 23.9 (3.0) 33.2 (2.9) 33.3 (3.0)
1) 23.8 (3.7) 22.9 (4.6) 26.5 (5.0) 25.1 (5.3)
49) 4.66 (0.67) 3.43 (0.50) 4.52 (0.61) 3.34 (0.47)
58) 5.62 (0.76) 4.00 (0.59) 5.63 (0.76) 4.06 (0.57)
06) 0.83 (0.07) 0.86 (0.06) 0.80 (0.05) 0.82 (0.06)
.0) 22 (5.9) 19 (4.7) 17 (4.6) 39 (9.6)
0.01 in 1986 and p < 0.001 in 1992, 1998, and 2006; kp < 0.001 in
I Z body mass index, FEV1 Z forced expiratory volume in 1 s,
us variables and with Chi-square for dichotomous variables. Dif-
Table 2 Characteristics of subjects included in the lon-
gitudinal analyses.
Males
(n Z 373)
Females
(n Z 407)
p-Valuea
AHR (ever) 82 (22.0) 88 (21.6) 0.90
AHR (at first
examination
of subject)
46 (12.3) 29 (7.1) 0.01
Rhinitis 137 (36.7) 162 (39.8) 0.42
Atopic dermatitis 48 (12.9) 76 (18.7) 0.03
Asthma 66 (17.7) 94 (23.1) 0.06
Ever smoking 174 (46.7) 247 (60.8) <0.001
Values are given as number of subjects (per cent within sex).
Definition of abbreviations: AHRZ airway hyperresponsiveness.
a Differences between sexes are tested using Chi-square tests.
Airway hyperresponsiveness and lung function 755subsequent examinations. Subjects with a positive AHR test
at the first examination were older at the first examination
(mean age [SD] 15.5 [5.4]) than subjects with ever AHR but
a negative test at the first examination (mean age [SD] 13.5
[3.9]), p Z 0.01.
AHR and lung function development
We used a repeated measures regression model to examine
the effect of AHR on lung function development adjusted
for asthma and smoking. The model demonstrated a dif-
ference in growth rates in FEV1 until age 18 between males
and females of 154 ml/year (p < 0.001), with males pre-
senting with higher growth rates compared to females, as
expected (374 ml/year vs. 219 ml/year).
There was no difference in FEV1 values at age 7 be-
tween subjects with and without AHR, but subjects
with ever AHR had a significant reduction in growth
rate of FEV1 of 23 ml/year until age 18 (p Z 0.015).
Estimates of the effect of asthma (p Z 0.7) and smokingFigure 1 Growth pattern in FEV1 and the effect of AHR on
FEV1 development. Estimated FEV1 was calculated from the
regression analysis for males and females with and without
AHR, respectively. Error bars indicate 95% confidence intervals.
Definition of abbreviations: AHR Z airway hyper-
responsiveness, FEV1 Z forced expiratory volume in 1 s.(p Z 0.6) on growth rate were insignificant in the model
with AHR.
After age 18, both males and females presented with
slow annual declines in FEV1 of 18 ml (p < 0.001). No
difference could be demonstrated between sexes. AHR
had no effect on this rate of decline (p Z 0.6), thus
the slopes for the subjects with and without AHR were
parallel after age 18. Although there was a tendency to-
wards smoking accelerating the decline in FEV1 after the
age of 18, it did not reach statistical significance
(p Z 0.1). No effect of asthma could be demonstrated on
the rates of decline (p Z 0.9). Confounding by height
was found not to influence the results (p Z 0.2). The
growth pattern of FEV1 according to sex and AHR status is
given in Fig. 1.
Analysing the data with AHR at the first examination as
explanatory variable, thus with AHR as predictor of the
subsequent lung function development, the results indi-
cated that the AHR precedes, and as such predicts, the
impaired lung function growth, although it did not reach
statistical significance (p Z 0.054).Discussion
In this longitudinal study of lung function development from
childhood to adulthood in a general population, we found
that AHR is independently associated with reduced rates of
lung function growth and causes deficits in maximal lung
function attained. Our results were suggestive of AHR being
an independent predictor for the subsequent lung function
development, which indicates a temporal relation between
AHR and lung function growth in children and adolescents
with AHR preceding the lung function changes. A temporal
relationship between presence of AHR and subsequently
reduced FEV1 level two years later has been demonstrated
in adolescents [5], but we were now able to demonstrate
the long-term consequences of this relationship. The
adverse effect of AHR on lung function growth resulted in
deficits in maximal attained level of lung function at age
18, as seen in a previous study [6], which persisted through
the rest of our follow-up period. The oldest subjects in our
cohort were followed until age 37, and we were not able to
demonstrate any effect of AHR on lung function decline in
adulthood so far. An association between AHR and lung
function decline in adults has been found previously in
older general population cohorts [7]. It is most likely, that
our follow-up period is still too short to demonstrate this
association.
Several general population studies have investigated
lung function development from infancy through childhood
or from childhood through adolescence, but so far the
follow-up periods have not covered ages beyond early
adulthood [5,15e17]. Consequently, these studies cannot
demonstrate the long-term consequences of lung function
development in childhood and adolescence on later lung
function. Other studies are initiated at an older age
[18,19], and thus cannot demonstrate factors of impor-
tance for lung function development during the growth
phase. Only few studies on lung function development are
based on longitudinal measurements from childhood to
older ages [3,20].
756 L. Harmsen et al.Our repeated measures regression model revealed a
gender difference in the FEV1 growth rate until age 18,
whereafter males and females presented with similar slow
annual declines in FEV1. In contrast to our findings, Wang
et al. [6] have previously reported from a large cohort study
based on the Vlagtwedde/Vlaardingen study in the
Netherlands that the level of FEV1 has already peaked by
age 15 in females, whereas the peak in males was not
observed until age 20. However, our findings are in accor-
dance with previous observations females reported by
Tager et al. [1] from the East Boston Study. The reasons for
these discrepancies in observations are unclear, but may be
related to differences in sampling of the cohorts, including
amount of data in the age range of greatest interest and
age range, and differences in exposures, as also reflected in
comparisons of reference values for lung function in young
adults [21].
Even though our study was consistent with previous
studies, there are some limitations to note. Most notably is
the change in use of bronchoprovocational agent during the
study from histamine to methacholine. Histamine and
methacholine are equivalent in producing bronchocon-
striction at nearly the same concentrations and doses, and
at the same weight as their molecular weights are relatively
close. Accordingly, tests with histamine and methacholine
are comparable, and they are most likely related to the
same pathological airway processes and probably inter-
changeable [22,23].
Our findings of AHR from the first examination in 1986
were possibly influenced by the restricted permission on
the AHR test in terms of the low-concentration cut-off (20%
fall in FEV1 caused by less than 8 mg/ml histamine). The
cut-off employed for the subsequent examinations, i.e. a
20% fall in FEV1 caused by less than 16 mg/ml of histamine
had most likely detected more AHR positive subjects and
could have strengthened the results on AHR as a predictor
of impaired lung function growth.
Moreover, there was a trend, but no significant effect
of smoking on lung function decline could be demon-
strated. Again, it is possible that the cohort is still too
young for this effect to be demonstrated. Besides AHR,
asthma, and active smoking, other factors such as passive
tobacco exposure and respiratory infections in infancy
have been shown to have an effect on lung function
development, including some we have not been able to
assess in this cohort. We had no measurements of indoor
or outdoor pollution. However, as all subjects in the
cohort resided in the capital of Denmark, differences in
levels of at least outdoor pollution between subjects were
most likely minor.
In conclusion, we found that AHR had an independent
deleterious effect on lung function development over the
ages from 7 to 37 years resulting in a lower maximal
attained lung function and persistently lower levels of lung
function after this peak. The effect persisted after
adjustment for asthma and smoking.Conflict of interest statement
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